HLA-G 14BP Polymorphism Matching Protects against Development of Post-Transplant Malignancy Following Heart Transplantation
Post-transplant malignancy (PTM) is a major cause of morbidity and mortality following transplantation. Human leukocyte antigen G (HLA-G) is an immune checkpoint molecule that reduces allograft rejection by dampening the host immune response. Reports suggest HLA-G may be utilized by malignant cells to evade the immune system and promote cancer development. Our objective was to evaluate HLA-G donor/recipient genotype matching and development of PTM following heart transplantation.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: M.B. Adamson, R.V. Ribeiro, F. Yu, J. Lazarte, K. Runeckles, C. Manlhiot, V. Rao, D. Delgado Tags: 330 Source Type: research
More News: Bone Graft | Cancer | Cancer & Oncology | Cardiology | Heart | Heart Transplant | Lung Transplant | Transplant Surgery | Transplants